{'fraction_non_alphanumeric': 0.02526595744680851, 'fraction_numerical': 0.005319148936170213, 'mean_word_length': 5.38135593220339, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Antiblastic agent-induced vomiting: possibilities of its prevention and alizapride therapy].

The spread of cytostatics has made the search for safe drugs for the prevention and treatment of induced vomiting important. In the present study, the protective (prophylactic and therapeutic) effect of Alizapride has been examined. Ten oncological patients of average age 60 were treated with a total of 30 cycles according to the commonest protocols of drugs with varying emetic potential (from bland bleomycin type to high cisplatin type). The patients were subdivided into two groups: a) prophylaxis before and after chemotherapy; b) treatment only as needed. Analysis of the data showed excellent tolerance and significant effectiveness in both groups.